| |
| |
|
| Insider
Information: |
Niven Ralph |
| Relationship: |
|
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
104,874 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$16,935 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
104,874 |
|
|
| Total
Value |
$16,935 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Windtree Therapeutics Inc |
WINT |
SVP-Preclinical Dev-Fo... |
2005-06-01 |
103,265 |
2004-06-08 |
0 |
Premium* |
|
|
Aerovate Therapeutics, Inc. |
AVTE |
|
2024-02-05 |
1,609 |
2022-08-18 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
52 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AVTE |
Aerovate Therapeutics, In... |
Chief Scientific Officer |
• – – |
2022-08-18 |
4 |
AS |
$21.18 |
$47,657 |
D/D |
(2,250) |
1,609 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
Chief Scientific Officer |
• – – |
2022-09-06 |
4 |
AS |
$19.00 |
$42,750 |
D/D |
(2,250) |
1,609 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF SCIENTIFIC OFFICER |
• – – |
2022-10-05 |
4 |
AS |
$15.71 |
$35,447 |
D/D |
(2,250) |
1,609 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF SCIENTIFIC OFFICER |
• – – |
2022-11-07 |
4 |
AS |
$17.09 |
$43,194 |
D/D |
(2,250) |
1,609 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF SCIENTIFIC OFFICER |
• – – |
2022-12-05 |
4 |
AS |
$17.38 |
$39,114 |
D/D |
(2,250) |
1,609 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF SCIENTIFIC OFFICER |
• – – |
2023-01-05 |
4 |
AS |
$26.40 |
$59,405 |
D/D |
(2,250) |
1,609 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF SCIENTIFIC OFFICER |
• – – |
2023-02-06 |
4 |
AS |
$24.27 |
$54,612 |
D/D |
(2,250) |
1,609 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF SCIENTIFIC OFFICER |
• – – |
2023-03-06 |
4 |
AS |
$23.73 |
$53,440 |
D/D |
(2,250) |
1,609 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF SCIENTIFIC OFFICER |
• – – |
2023-04-05 |
4 |
AS |
$17.91 |
$40,942 |
D/D |
(2,250) |
1,609 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF SCIENTIFIC OFFICER |
• – – |
2023-05-05 |
4 |
AS |
$20.79 |
$46,957 |
D/D |
(2,250) |
1,609 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF SCIENTIFIC OFFICER |
• – – |
2023-06-05 |
4 |
AS |
$16.26 |
$36,576 |
D/D |
(2,250) |
1,609 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF SCIENTIFIC OFFICER |
• – – |
2023-07-05 |
4 |
AS |
$17.23 |
$38,915 |
D/D |
(2,250) |
1,609 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF SCIENTIFIC OFFICER |
• – – |
2023-11-22 |
4 |
AS |
$15.00 |
$207,000 |
D/D |
(13,800) |
1,609 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF SCIENTIFIC OFFICER |
• – – |
2023-12-05 |
4 |
AS |
$16.30 |
$74,996 |
D/D |
(4,600) |
1,609 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF SCIENTIFIC OFFICER |
• – – |
2024-01-05 |
4 |
AS |
$18.67 |
$88,116 |
D/D |
(4,600) |
1,609 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF SCIENTIFIC OFFICER |
• – – |
2024-02-05 |
4 |
AS |
$17.45 |
$80,249 |
D/D |
(4,600) |
1,609 |
0 |
- |
|
| WINT |
Windtree Therapeutics Inc |
Sr. VP Preclinical Development |
• – – |
2003-12-02 |
4 |
A |
$3.22 |
$4,495 |
D/D |
1,140 |
3,140 |
|
- |
|
| WINT |
Windtree Therapeutics Inc |
Sr. VP Preclinical Development |
• – – |
2004-01-23 |
4 |
A |
$8.11 |
$1,501 |
D/D |
185 |
3,325 |
|
- |
|
| WINT |
Windtree Therapeutics Inc |
Sr. VP Preclinical Development |
• – – |
2004-04-22 |
4 |
A |
$11.65 |
$1,619 |
D/D |
139 |
3,464 |
|
- |
|
| AVTE |
Aerovate Therapeutics, In... |
Chief Scientific Officer |
• – – |
2022-08-18 |
4 |
OE |
$1.74 |
$4,555 |
D/D |
2,250 |
3,859 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
Chief Scientific Officer |
• – – |
2022-09-06 |
4 |
OE |
$1.74 |
$4,555 |
D/D |
2,250 |
3,859 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF SCIENTIFIC OFFICER |
• – – |
2022-10-05 |
4 |
OE |
$1.74 |
$4,555 |
D/D |
2,250 |
3,859 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF SCIENTIFIC OFFICER |
• – – |
2022-11-07 |
4 |
OE |
$1.74 |
$4,555 |
D/D |
2,250 |
3,859 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF SCIENTIFIC OFFICER |
• – – |
2022-12-05 |
4 |
OE |
$1.74 |
$4,555 |
D/D |
2,250 |
3,859 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF SCIENTIFIC OFFICER |
• – – |
2023-01-05 |
4 |
OE |
$1.74 |
$4,555 |
D/D |
2,250 |
3,859 |
0 |
- |
|
52 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
